Our R&D Pipeline

Phase II Ready Small Molecule: MCH-1 Antagonist CSTI-100 for Nonalcoholic Steatohepatitis (NASH) and Inflammatory Bowel Disease (IBD)

  • CSTI-100 is expected to be a multi-factorial treatment for NASH by simultaneously reducing caloric intake, improving insulin sensitivity, and diminishing inflammatory and fibrotic pathways.
  • Literature and preliminary data shows IBD as another indication.
  • CSTI-100 is safe and well tolerated in Phase I clinical studies, t1/2 of 26 h.
  • Active areas of large licensing deals in recent years.
  • *We welcome academic researchers to contact us for the possibility of a collaboration to study CSTI-100. Click here for more information on CSTI-100.

    Phase II ready assset - Triple Reuptake Inhibitor CSTI-500 (a.k.a.BMS-866949)

  • Unique “triple” pharmacology profile: high serotonin transporter (SERT), low-mid norepinephrine (NET), and dose-dependent dialing in of dopamine transporter (DAT) occupancy
  • Long elimination half-life (~48 hours) and no abuse potential
  • Potential for highly differentiated treatment for multiple CNS indications, including: including: difficult-to-treat major depressive disorder, ADHD and other CNS disorders
  • Phase I clinical development and in vivo CNS receptor occupancy studies completed to show unique profile and guide Phase II dosing
  • The technology is the output of a collaboration between AMRI and Bristol-Myers Squibb
  • Novel targeting of the 5-HT3 Receptor to Treat Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) and IBS with alternating constipation and diarrhea (IBS-M).

  • Irritable Bowel Syndrome (IBS) is a major functional disorder affecting 12% of adults with considerable economic burden (>$25 billion)
  • There is currently no effective treatment widely available
  • Novel targeting of 5-HT3 receptor using a partial agonist such as CSTI-300 delivering potential best-in-class treatment
  • CSTI-300 represents a new clinical approach clearly differentiated from 5-HT3 receptor antagonists. Designed to avoid the side effects associated with maximal 5-HT3 receptor inhibition (i.e. severe constipation, ischemic colitis)
  • Excellent drug properties and safety profile
  • Please contact info@consynance.com for a non-confidential deck